Evidence map›Paper›PMID 41010845›Full record

ArticleJournal of clinical medicine2025

Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network.

Márk Hernádfői, Márton Szabados, Edit Brückner, Ágnes Varga, Péter Hauser, Gábor Ottóffy, Ágnes Vojcek, Krisztina Csanádi, Gabriella Kertész, Zsuzsanna Jakab and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Márk HernádfőiCentre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.
Márton SzabadosCentre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.
Edit BrücknerPediatric Center, Semmelweis University, 1094 Budapest, Hungary.
Ágnes VargaVelkey László Children's Health Center, B.A.Z. County Central Hospital and University Teaching Hospital, 3529 Miskolc, Hungary.
Péter HauserPediatric Center, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0002-8307-8975
Gábor OttóffyDepartment of Pediatrics, University of Pécs Medical School, 7623 Pécs, Hungary.ORCID 0000-0002-8990-6620
Ágnes VojcekDepartment of Pediatrics, University of Pécs Medical School, 7623 Pécs, Hungary.
Krisztina CsanádiHeim Pál National Pediatric Institute, 1089 Budapest, Hungary.
Gabriella KertészDepartment of Pediatric Bone Marrow & Stem Cell Transplant, South-Pest Hospital Centre-National Institute for Infectology and Hematology, 1097 Budapest, Hungary.ORCID 0000-0001-6071-8290
Zsuzsanna JakabPediatric Center, Semmelweis University, 1094 Budapest, Hungary.ORCID 0000-0002-5410-1187
Gergely AgócsCentre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0003-2489-3790
Miklós GaramiCentre for Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0003-4298-2746

Funding

National Research, Development and Innovation Fund KDP-12-3/PALY-2022Recordati Rare Diseases NA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-GD2 monoclonal antibodydinutuximab betahigh-risk neuroblastomaimmunotherapymaintenance therapyrefractory and relapsed neuroblastoma

Identifiers

PMID41010845
PMCPMC12471212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.